Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

PD-L1 antibody (C-Term)

KO Validated PD-L1 Reactivity: Human WB, FACS, ICC, IF, IHC (p), IHC (fro) Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN2855940
  • Target See all PD-L1 Antibodies
    PD-L1 (CD274 (PD-L1))
    Binding Specificity
    • 29
    • 16
    • 15
    • 12
    • 11
    • 11
    • 8
    • 7
    • 7
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reactivity
    • 166
    • 106
    • 63
    • 7
    • 6
    • 5
    • 5
    • 1
    • 1
    Human
    Host
    • 125
    • 59
    • 15
    • 4
    • 4
    • 1
    Rabbit
    Clonality
    • 107
    • 99
    • 2
    Polyclonal
    Conjugate
    • 96
    • 14
    • 13
    • 11
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    This PD-L1 antibody is un-conjugated
    Application
    • 137
    • 101
    • 60
    • 40
    • 36
    • 28
    • 16
    • 16
    • 15
    • 14
    • 9
    • 7
    • 5
    • 4
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Cross-Reactivity
    Human
    Characteristics
    Rabbit Polyclonal antibody to PD-L1 (CD274 Molecule)
    PD-L1 antibody
    Purification
    Purified by antigen-affinity chromatography.
    Grade
    KO Validated
    Immunogen
    Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human PD-L1. The exact sequence is proprietary.
    Isotype
    IgG
    Top Product
    Discover our top product PD-L1 Primary Antibody
  • Application Notes
    WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
    Comment

    Positive Control: MDA-MB-231 (24μg/ml Tunicamycin treatment for 16 hr) , MDA-MB-231 , A431(100 ng/mL IFN-gamma treatment for 48 hr)

    Validation: Comparison, KO/KD, Orthogonal, Overexpression

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.29 mg/mL
    Buffer
    1XPBS, 1 % BSA, 20 % Glycerol ( pH 7), 0.025 % ProClin 300
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
  • Kim, Kim, Kim, Kim, Kim: "Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder." in: Journal of clinical medicine, Vol. 9, Issue 5, (2020) (PubMed).

    Qin, Wang, Ye, Li, Chen, Wang, Qin, Zhang, Li, Long, Hu, Shi, Li, Zhang, Zhai, Tang, Kang, Lan, Xie, Lu, Deng: "NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer." in: Nature communications, Vol. 11, Issue 1, pp. 1669, (2020) (PubMed).

    Gondhowiardjo, Handoko, Adham, Rachmadi, Kodrat, Tobing, Haryoga, Dwiyono, Kristian, Mayang Permata: "Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer." in: PLoS ONE, Vol. 15, Issue 3, pp. e0230449, (2020) (PubMed).

    Pan, Wu, Kan, Li, Chang, Wu, Li, Ou-Yang, Hou, Yip, Luo: "Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer." in: Cancers, Vol. 12, Issue 1, (2019) (PubMed).

    Cha, Yang, Xia, Wei, Chan, Lim, Li, Kim, Chang, Lee, Hsu, Wang, Kuo, Chang, Hadad, Purdie, McCoy, Cai, Tu, Litton, Mittendorf, Moulder, Symmans, Thompson, Piwnica-Worms, Chen, Khoo, Hung: "Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1." in: Molecular cell, Vol. 71, Issue 4, pp. 606-620.e7, (2019) (PubMed).

    Buisseret, Garaud, de Wind, Van den Eynden, Boisson, Solinas, Gu-Trantien, Naveaux, Lodewyckx, Duvillier, Craciun, Veys, Larsimont, Piccart-Gebhart, Stagg, Sotiriou, Willard-Gallo: "Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer." in: Oncoimmunology, Vol. 6, Issue 1, pp. e1257452, (2017) (PubMed).

    Lin, Sung, Hsieh, Tsai, Lai, Yang, Shen, Chen, Lee, Yeh, Chen: "High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma." in: PLoS ONE, Vol. 10, Issue 11, pp. e0142656, (2016) (PubMed).

  • Target
    PD-L1 (CD274 (PD-L1))
    Alternative Name
    CD274 molecule (PD-L1 Products)
    Synonyms
    B7-H antibody, B7H1 antibody, PD-L1 antibody, PDCD1L1 antibody, PDCD1LG1 antibody, PDL1 antibody, A530045L16Rik antibody, B7h1 antibody, Pdcd1l1 antibody, Pdcd1lg1 antibody, Pdl1 antibody, RGD1566211 antibody, CD274 molecule antibody, CD274 antigen antibody, programmed cell death 1 ligand 2 antibody, CD274 antibody, Cd274 antibody, PDCD1LG2 antibody
    Background
    Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.

    Cellular Localization: Isoform 1: Cell membrane, Single-pass type I membrane protein , Isoform 2: Endomembrane system, Single-pass type I membrane protein
    Molecular Weight
    33 kDa
    Gene ID
    29126
    UniProt
    Q9NZQ7
    Pathways
    Cancer Immune Checkpoints
You are here:
Support